Survivin expression is associated with bladder cancer presence, stage, progression, and mortality.
about
Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical TherapyPrognostic role of survivin in bladder cancer: a systematic review and meta-analysisPersonalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat.1,1-Bis(3'-indolyl)-1-(p-bromophenyl)methane and related compounds repress survivin and decrease gamma-radiation-induced survivin in colon and pancreatic cancer cellsBladder tumor markers: from hematuria to molecular diagnostics--where do we stand?Clinicopathological and prognostic significance of survivin over-expression in patients with esophageal squamous cell carcinoma: a meta-analysis.Bladder cancer: a simple model becomes complex.Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing.Biological markers in the diagnosis of recurrent bladder cancer: an overview.Predicting survival after radical cystectomy for bladder cancer.Bladder cancer biomarkers and their role in surveillance and screening.C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy.Molecular markers for detection, surveillance and prognostication of bladder cancer.miR-138-5p contributes to cell proliferation and invasion by targeting Survivin in bladder cancer cells.HIF-1, GLUT1, endoglin, and BIRC5 expression in urine samples obtained from patients with bladder malignancies - after photodynamic diagnosis (PDD).NF-κB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo.Ubiquitin-like protein FAT10 promotes bladder cancer progression by stabilizing survivin.Developing biomarkers for improved diagnosis and treatment outcome monitoring of bladder cancer.Immunohistochemical biomarkers for bladder cancer prognosis.Biomolecular predictors of urothelial cancer behavior and treatment outcomes.Urinary protein biomarkers of cancer.Functional polymorphisms in the matrix metalloproteinase genes and their association with bladder cancer risk and recurrence: a mini-review.Predictive markers in bladder cancer: do we have molecular markers ready for clinical use?Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma.The effects of hyperoside on apoptosis and the expression of Fas/FasL and survivin in SW579 human thyroid squamous cell carcinoma cell lineThe effects of STAT3 and Survivin silencing on the growth of human bladder carcinoma cells.Enhanced inhibition of bladder cancer cell growth by simultaneous knockdown of antiapoptotic Bcl-xL and survivin in combination with chemotherapy.Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells.Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer.Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study.CD147 as a novel biomarker for predicting the prognosis and clinicopathological features of bladder cancer: a meta-analysis.Alternating expression levels of WWOX tumor suppressor and cancer-related genes in patients with bladder cancer.Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches.Expression of vimentin and survivin in clear cell renal cell carcinoma and correlation with p53.Role of Non-Coding RNAs in the Etiology of Bladder Cancer.Predictors of cancer-specific mortality after disease recurrence following radical cystectomy.Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines.Survivin SNP-carcinogen interactions in oral cancer.Survivin T9809C, an SNP located in 3'-UTR, displays a correlation with the risk and clinicopathological development of hepatocellular carcinoma.Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility.
P2860
Q26774965-CA113C65-F9E5-4B7A-9287-F61999BE51E2Q27028122-12503EA6-05CD-4720-B30C-E4E5CD0E4ADFQ30437629-A61E7632-9E93-4107-AF2F-90484459C378Q33748743-7DD5C4AB-B571-4E10-BE5E-18FEB1906F6EQ33915293-41A0086D-C056-4FC4-AAC1-B8E17ADD8D62Q34427388-8A80B908-7796-41E6-9E6C-4B04195AA3ABQ36108115-0AFB52A8-D8FA-4AAF-8AAB-202632D1AE0CQ36826036-6D72BF29-53CF-4F04-94FF-563BEED5F025Q37035277-B38A6540-E141-48A2-9527-4126DF2E03E9Q37103989-8EC98CD5-83D0-49B8-BB6B-45BC1863B376Q37361497-525AB80F-0685-43EE-86F1-CB357819AAD3Q37407271-F1102EE9-5F0D-4881-B39C-89E35C523405Q37418122-78840B21-2945-4630-A158-F7EBD5B5B811Q37508895-5154B77A-016A-4104-A6D3-B3611117AC21Q37579133-548D35E2-CA1B-4C56-AAD9-D8789BE55898Q37615242-CDA71DC0-86A4-4B2A-902C-F4AF75D6539BQ37697183-CDC2999D-D945-4058-ADE8-9E0DE8E3C0BDQ37743536-70747F53-D622-4F56-B05E-5CBA4228FEB5Q37902697-FD3AC8AE-0C2F-4BD2-AD27-5485DB72A971Q37987066-DA06938B-1939-40C8-AAE5-5286C01108E4Q38089063-14AE7D18-5B54-4D69-B204-C983A9AC48BAQ38196442-004BAD20-C0F1-4647-BB66-BC9F549FB3B2Q38230912-A4D9279F-F6A4-4B47-9DEB-1707413CF250Q38399485-F8EDC181-4B8D-4B19-A694-B2DDB9AA8D40Q38695452-665C7319-D9E5-4D02-8F8E-628788062905Q39024758-524CA7B1-1EC8-4D51-8F7F-794292794D74Q39142102-E3A13A95-D723-438A-BBBC-48A1061ED92AQ39314317-82A32DE9-1BE9-4114-8B8E-8BB22D291F2BQ39451790-C110D527-48FD-48BB-BFE6-41BF3B49B8ABQ40873267-869C445A-51EF-49D8-8FB3-E89A08CCC57BQ41914358-12FC2F16-D248-4EA5-AEE2-2EBA91FB6F32Q42049504-6495C8DE-B71C-4A2B-8029-C0B313C02DF6Q43498496-13F3107B-6DCC-479C-9628-75A348B4AC47Q45866814-AE24A227-6AB0-43BD-94C9-1CF544703EFDQ46236214-E258B997-1B81-4241-93FE-5562D55CAEE2Q46489162-B90467CB-DA14-4273-97AD-6D351E942FE1Q49805034-6E4EFF77-53B9-47FD-BDD6-ECB034CB5B3BQ53274551-76C30719-EF7D-4A16-AE00-71AA49EB01F3Q54340913-6C8B2B4E-D069-41B2-8FAA-3B62435F2340Q54397539-9B046DBC-78E1-4445-8459-B22DEAD2F6FE
P2860
Survivin expression is associated with bladder cancer presence, stage, progression, and mortality.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Survivin expression is associa ...... e, progression, and mortality.
@en
type
label
Survivin expression is associa ...... e, progression, and mortality.
@en
prefLabel
Survivin expression is associa ...... e, progression, and mortality.
@en
P2093
P356
P1433
P1476
Survivin expression is associa ...... e, progression, and mortality.
@en
P2093
Arthur I Sagalowsky
Osamah Saeedi
Pierre I Karakiewicz
Raheela Ashfaq
Shahrokh F Shariat
P304
P356
10.1002/CNCR.22521
P407
P50
P577
2007-03-01T00:00:00Z